We are live on ! Find out more
HRMY icon

Harmony Biosciences

84 hedge funds and large institutions have $790M invested in Harmony Biosciences in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 6

256% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 9

47% more funds holding

Funds holding: 5784 (+27)

0.92% more ownership

Funds ownership: 48.28%49.2% (+0.92%)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

13% less capital invested

Capital invested by funds: $907M → $790M (-$117M)

Holders
84
Holders Change
+27
Holders Change %
+47.37%
% of All Funds
1.46%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
33
Increased
32
Reduced
9
Closed
6
Calls
Puts
Net Calls
Net Calls Change

HRMY Hedge Fund Activity: Q2 2021 in Review

84 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q2 2021, worth a combined $790M — down 13% from $907M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new HRMY positions and 6 closed out — a net gain of 27 holders — while 32 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $30.2M. The largest seller was Fidelity Investments, cutting an estimated $69.3M.

  • 84 institutional investors held Harmony Biosciences (HRMY) as of Q2 2021, up from 57 in Q1 2021.
  • Funds reported $790M of Harmony Biosciences stock for Q2 2021, down 13% quarter-over-quarter.
  • 33 funds opened new Harmony Biosciences positions in Q2 2021 and 6 closed out, a net change of +27 holders.
  • The largest Harmony Biosciences buyer in Q2 2021 was BlackRock, an estimated $30.2M added.
  • The largest Harmony Biosciences seller in Q2 2021 was Fidelity Investments, an estimated $69.3M sold.

Based on aggregated 13F filings for Q2 2021.